In prior work we demonstrated that loss of E2F transcription factors inhibits metastasis. Here we address the mechanisms for this phenotype and identify the E2F regulated genes that coordinate tumor cell metastasis. Transcriptomic profiling of E2F1 knockout tumors identified a role for E2F1 as a master regulator of a suite of pro-metastatic genes, but also uncovered E2F1 target genes with an unknown role in pulmonary metastasis. High expression of one of these genes, Fgf13, is associated with early human breast cancer metastasis in a clinical dataset. Together these data led to the hypothesis that Fgf13 is critical for breast cancer metastasis, and that upregulation of Fgf13 may partially explain how E2F1 promotes breast cancer metastasis. To test this hypothesis we ablated Fgf13 via CRISPR. Deletion of Fgf13 in a MMTV-PyMT breast cancer cell line reduces the frequency of pulmonary metastasis. In addition, loss of Fgf13 reduced in vitro cell migration, suggesting that Fgf13 may be critical for tumor cells to invade out of and escape the primary tumor. The significance of this work is twofold: we have both uncovered genomic features by which E2F1 regulates metastasis and we have identified new pro-metastatic functions for the E2F1 target gene Fgf13.
INTRODUCTION
Breast cancer progression to metastatic disease is associated with poor prognosis, with only 22% of the patients surviving five years 54 . As a result, there is a critical need to understand the molecular mechanisms that regulate metastasis. High throughput transcriptomic assays have been pivotal in understanding alterations in the transcriptional programs of cancer cells during the various steps of metastasis. Repeated selection of cells with the propensity for organ-specific metastasis 7, 34, 47 led to the discovery of transcriptional signatures unique to each metastatic site with characteristic transcriptomic changes 51 . Other studies have combined clinical observations with gene expression profiling to generate gene signatures that predict progression to metastasis 4, 68, 74 . Finally, gene expression profiling has been used to identify genes involved in metastasis which were then validated in genetically engineered mouse models of breast cancer 2, 11, 30, 71 .
One of the best characterized models of breast cancer metastasis is the MMTV-PyMT system where the expression of the polyoma virus middle T antigen is expressed under the control of the mouse mammary tumor virus promoter / enhancer 24 . Expression of the middle T antigen results in activation of key signaling pathways including Ras, PI3K/AKT and PLC-γ.
These transgenic mice rapidly develop multifocal mammary tumors and develop pulmonary metastasis at endpoint with nearly 100% penetrance. Our recent work highlighted the similarities of MMTV-PyMT tumors to human breast cancer and identified shared gene expression alterations between this mouse model and human disease 28 . One example is our observation that E2F pathway signatures were elevated in the MMTV-PyMT model, and we ultimately validated the role for E2F1, E2F3, and E2F3 in tumor progression using mouse models 28, 30 . E2F transcription factors are canonically involved in the G1/S transition, ultimately either promoting (E2F1-3a) or suppressing (E2F3b-8) cell cycle progression 3, 13, 39 . In this study we expand upon this theme to demonstrate a role for the activator class of E2Fs in tumor progression independent of their role in cell cycle progression.
Interbreeding MMTV-PyMT mice with mice null for E2F1 16 , E2F2 49 and E2F3 32 resulted in alterations in mammary gland development, tumor latency, histology, and vascularization 29, 66 .
In addition to, or perhaps as an effect of, the role of E2F1 and E2F2 on these tumor phenotypes, E2F1 and E2F2 deletion reduced metastatic capacity accompanied by a decrease in circulating tumor cells. This led to the hypothesis that the E2F transcription factors regulate tumor cell intrinsic gene expression programs that are critical for metastatic progression.
Given that E2F transcription factors have been demonstrated to bind thousands of individual target genes 5 , we sought to characterize the gene expression profiles of E2F1 -/-MMTV-PyMT tumors. We hypothesized that this approach would allow us to identify E2F1mediated transcriptional programs which contribute to metastasis. This would allow us to identify E2F1 target genes which were previously implicated in breast cancer metastasis but would also allow to identify novel metastasis driver genes. In line with this, we have identified a suite of E2F1 target genes which have been previously implicated in breast cancer metastasis, suggesting that E2F1 may be a master regulator of breast cancer metastasis. In addition, this analysis has also identified a new role for the E2F1 target gene fibroblast growth factor 13 (Fgf13) in breast cancer metastasis.
Results

Genomic Comparison of E2F WT/WT and E2F -/-Tumors
To determine the global gene expression response to E2F loss, we analyzed MMTV-PyMT tumors from E2F WT/WT , E2F1 -/-, E2F2 -/-, and E2F3 +/backgrounds on Affymetrix microarrays. Using an unsupervised classed discovery approach 73 , we investigated the gene expression relationships amongst the various tumors. We used 1000 iterations of data resampling to measure the frequency of co-clustering across 2-10 clusters. Examining potential classes using empirical cumulative distribution functions (CDF) showed that maximum CDF was reached with four clusters ( Figure 1A ). This suggests that this cohort of tumors can be divided into 4 distinct clusters, and adding additional clusters will have no statistically significant value 73 . To measure the correlation between samples within each cluster, we used silhouette width 58 ( Figure 1B ).
Silhouette width demonstrated the strongest correlations were present in cluster 1. In addition, we observe that the majority of samples have strong similarities to other samples within their assigned cluster. Sample co-clustering across the iterations of resampling is also illustrated in Figure 1C (see blue-white heatmap, where white shows 0% co-clustering to dark blue 100% clustering). Collectively, this analysis suggests the relationship of these tumors is best described by four clusters.
Examining these clusters in more detail ( Figure 1C ), we observe that gene expression patterns correlate with both tumor histology and genotype. For example, cluster 1 (purple) featured mainly tumors with squamous histology. The microacinar and papillary tumors appeared to separate by genotype; with the majority of E2F1 -/tumors ordered into cluster 2, E2F2 -/and E2F3 +/tumors in clusters 3 and 4, and E2F WT tumors were present in each cluster.
As an additional analysis, we also used a supervised approach using a published gene set for intrinsic classification of mouse mammary tumors 53 . To adjust for centering biases 83 and to enable accurate interpretation of this intrinsic analysis, we combined our dataset with published data 1, 2, 27 using Bayesian Factor Regression Modelling 10 (BFRM) to correct batch effects. This intrinsic analysis again separated tumors from the MMTV-PyMT model across distinct clusters ( Figure S1A ) and separated tumors according to histology and genotype ( Figure S1B ). In agreement with previous work 31 , the squamous tumors showed basal-like gene expression features ( Figure S1B , i). MMTV-PyMT E2F1 -/tumors clustered separately from other MMTV-PyMT tumors and showed high expression of some genes from the luminal cluster ( Figure S1B , ii). As expected, we did not detect evidence for claudin low tumors across any MMTV-PyMT tumors ( Figure S1B , iv). We did not observe differences in the proliferation cluster genes with regards to E2F status ( Figure S1B , iii). However, we did observe a difference by tumor histological subtype. Observing median expression of the proliferation signature genes 15 , microacinar and squamous tumors showed high expression, while papillary tumors had significantly lower median expression (p<.01 papillary vs microacinar, or papillary vs squamous; Figure S2A ). In agreement, retrospective analysis of tumor growth rate data, showed that papillary tumors progressed slower (days until 2,000 mm 3 ) than microacinar or squamous tumors ( Figure S2B ). Taken together, these data demonstrate unique features of tumor histologies and tumor genotypes; with E2F1 -/tumors exhibiting key molecular differences to other MMTV-
PyMT tumors.
To test if these gene expression differences in E2F1 -/tumors corresponded to differences in activation of major cell signaling pathways, we utilized a binary regression approach 6 to predict pathway activation across the MMTV-PyMT tumors. This revealed E2F1 -/tumors tend to have high activity of E2F4 ( Figure 2A ), and p53 ( Figure 2B ) pathways and low activity of pathways previously implicated in metastasis; the RhoA 78 , Src 50 , and Egfr 80 signaling pathways ( Figure 2C -E, respectively). Finally, using single sample gene set enrichment analysis (ssGSEA), we found that E2F1 -/tumors had significantly lower expression of the Hallmark Hypoxia 41 signature ( Figure 2F ); a process also associated with metastasis 42 .
To test for the genes that were significantly differentially regulated between E2F1 -/and E2F WT/WT tumors we used a supervised analysis 67 . Since we hypothesized that E2F1's role in regulating metastasis was by transcriptional activation of target genes, we were particularly interested in the 226 genes that were significantly downregulated in the E2F1 -/tumors. Many of the genes with low expression in E2F1 KO tumors were associated with hypoxia response (Supplemental file 1).
To begin characterizing these genes for metastatic potential, we used Kaplan Meier analysis of clinically and intrinsically annotated human breast cancer gene expression data 25 . To identify E2F1 target genes, we used ChIPBase 77 . Out of the 226 differentially regulated genes, 98 were E2F1 targets (supplemental file 1). From these, we focused on genes where high expression in tumors correlated with a decreased time to distant metastasis across all breast cancers as well as within with individual intrinsic subtypes of tumors. We identified 55 genes with pro-metastatic predictions (without discordant predictions in differing subtypes) (supplemental file 1); 34 of which had demonstrated E2F1 binding sites 5 . Using a Fisher's exact test, we observed that the distribution of direct E2F1 targets was significantly higher in the genes concordant with human breast cancer metastasis predictions (p=0.001) than genes either discordant or not predictive of human breast cancer metastasis. This suggested that the E2F1 target genes altered in these tumors are associated with human breast cancer metastatic potential and highlights that E2F1 may be a master regulator of breast cancer metastasis since it controls the expression of multiple pro-metastatic genes.
The 55 genes identified above that were associated with human breast cancer metastasis were examined in the literature to identify which of the molecular changes have already been demonstrated to regulate breast cancer metastasis in vivo. As depicted in Figure S3 , Vegfa 59 , Hbegf 84 , Hspb1 23 , Flt1 65 , L1cam 82 , and Plaur 76 had significantly lower expression (p<0.05) in E2F1 -/tumors and have all previously been shown to regulate breast cancer metastasis in vivo.
Additionally, there were genes with significantly lower expression in E2F1 -/tumors that had been shown to have in vitro invasion or migration function such as Areg 26 , Tead1 81 , Coro1C 69 , Lama5 22 , Tgm2 45 , and Fgf 7 79 (p<0.05, Figure S4 ). Taken together, this shows that E2F1 -/tumors have low expression of genes and pathways demonstrated to promote breast cancer metastasis.
Testing additional genes for metastatic function
Since we had identified a number of pathways and genes altered in E2F1 -/tumors which were previously identified as metastasis driver genes, we sought to identify novel regulators of metastasis from the genes downregulated in E2F1 -/tumors. Candidate genes for further testing were prioritized by selecting genes that had not previously been demonstrated to regulate breast cancer metastasis, that were E2F target genes, and correlated with decreased time to distant metastasis across several human breast cancer human breast cancer subtypes. With this pipeline we identified differential expression of fibroblast growth factor 13 (Fgf13). As shown in Figure   3A , expression was significantly reduced 1.4-fold in E2F1 -/tumors (q=0.01, p=0.02). Analysis of the 500 bp sequence upstream of the transcriptional start site (TSS) revealed seven E2F binding motifs in human and ten in the mouse sequence for this gene. High expression of Fgf13 was significantly associated with faster onset of distant metastasis across all cases of breast cancer ( Figure 3B ) but was not significant across all Er+ tumors ( Figure 3C ). However, it was significantly associated with accelerated time to distant metastasis in Er-tumors ( Figure 3D ).
Observing intrinsic subtypes, Fgf13 was not associated with metastasis of Luminal A tumors ( Figure 3E ). However, in Luminal B, Basal-like, and Her-2 enriched tumors high expression Fgf 13 was predictive of early onset metastasis ( Figure 3F -H respectively).
To test this gene for metastatic behavior, we utilized a PyMT-derived cell line (PyMT 419 cells) 44 and a CRISPR (clustered regularly interspaced short palindromic repeats) approach to create Fgf13 knockout cells. Figure 4A shows an example of sequence trace for Fgf13 control and a knockout lines. Western blot analysis confirmed that protein levels of Fgf13 were impacted by CRISPR gene editing ( Figure 4B ). In addition, we transduced our knockout lines with a vector to restore Fgf13 and confirmed re-addition by Fgf13 by western blot ( Figure 4B ).
We opted to assess metastatic capacity by tail vein injection. In this setting 50,000 cells were injected into the tail vein and lung colonization was examined 21 days later. In mice receiving control cells, robust metastatic colonization of the lungs was observed ( Figure 5A ). In addition, metastatic tumors were found sporadically throughout the mouse at other sites. Loss of Fgf13 dramatically limited the ability of the tumor cells to form metastases at the lung ( Figure   5B ) and re-expression of Fgf13 restored metastasis ( Figure 5C ). There was a significant reduction in the number of lesions present in the lungs for mice receiving Fgf13 -/cells ( Figure   5D ). Together, these results show that Fgf13 regulates breast cancer pulmonary metastasis.
Investigating Fgf13 function
To predict Fgf13 function, we examined the Fgf13 covariance network using WGCNA analysis of primary MMTV-PyMT E2F wild type tumors (supplemental file 2), identifying 38 probes corresponding to 35 genes that tightly correlate with Fgf13 expression (gs threshold =0.6, p-value <0.0005). MSigDB revealed a significant association with a signature for genes upregulated in invasive ductal carcinoma relative to ductal carcinoma in situ (Supplemental File 3, p-value =1.02 e -4 , FDR q-value =3.97 e -2 ). We were also interested to note association with the Rac1 cell motility pathway (Supplemental File 2, p-value = 5.38 e -7 , FDR q-value = 1.29 e -3 ).
Key to this association was strong covariance with Rac1 (gs=0.60), the GTPase activating protein chimerin 1 (Chn1, gs=0.60), and Wasf1 (which acts downstream of Rac1 to regulate the cytoskeleton, gs=0.61). Matching this association, Fgf13 was part of the KEGG pathway for regulation of the actin cytoskeleton. Testing these alterations for the presence of an interaction network with Rb-E2F1 and the pathways altered in E2F1 -/tumors illustrated a relationship between Fgf13, cytoskeleton and motility genes, and pathways predicted to have low activity in E2F1 -/tumors ( Figure 6A ). WGCNA identified additional genes with cytoskeleton regulatory function such Tubulin beta 6 (Tubb6) and microtubule-associated protein 1B (Mtap1B). In addition, given Fgf13's published role in neuronal cell differentiation 75 , we were interested to note this as another prominent theme amongst the Fgf13 metagene (Table 1) . In testing these genes as a signature for association with human breast cancer metastasis events, we found that high expression of these genes was significantly associated with a shorter time to distant metastasis across breast cancer tumors ( Figure 6B ).
To test for a possible function in cell motility, we assessed the migratory capacity of the MMTV-PyMT control cells and Fgf13 KO cells using a scratch assay ( Figure 6C ). While control cells were able to close the scratch at 18 hours, the Fgf13 KO clones demonstrated a significant defect in cell migration. Re-expression of Fgf13 restored migratory capacity of these cells, with wounds nearly closed by 18 hours ( Figure 6D ). Together, these data confirm the bioinformatic predictions that Fgf13 functions in cell migration and provides a likely explanation for the metastasis defects associated with Fgf13 loss.
DISCUSSION
Using a transcriptomic approach, we investigated the mechanism by which E2Fs regulate breast cancer metastasis 30 . Here we used bioinformatic analysis to compare global gene expression differences between E2F WT/WT MMTV-PyMT tumors and E2F1 -/-MMTV-PyMT tumors. We demonstrated that loss of E2F1 led to decreased activity in several key signaling pathways previously demonstrated to regulate metastasis ( Figure 2) . Many of the genes downregulated in E2F1 -/tumors correlate with a faster progression to metastatic disease in human clinical data were significantly associated with the gene expression response to hypoxia (Supplemental File 1).
The majority of the genes associated with hypoxia were also direct E2F1 target genes.
Hypoxia has been described as a master regulator of metastasis due to the result of gene expression changes brought about by hypoxia response 42 . These gene expression changes enable tumor cells to progress through multiple checkpoints during the metastatic cascade. This includes promoting angiogenesis, epithelial to mesenchymal transition, tumor cell invasion, remodeling of the extra cellular matrix, and increasing cell migration 20, 37, 42, 62 . Hypoxia also upregulates genes which facilitate tumor cell intravasation, survival in the blood stream, extravasation and colonization at distant organs 42 . Consistent with processes associated with hypoxia response, we previously observed angiogenesis defects and a decrease in circulating tumor cells suggesting intravasation defects or an inability for metastatic cells to resist anoikis 29 .
Our prior work had shown that these vascular defects were associated with a significant reduction in the major angiogenesis signaling molecule, Vegfa. This study expands on this finding and adds to the growing body of research that has demonstrated E2F1 as a key regulator of angiogenesis 14, 16, 18, 55 ; suggesting E2F1 regulates many genes within the hypoxia response program to potentially coordinate the development of tumor vasculature.
In addition to hypoxia response, E2F1 -/tumors had significantly lower expression of genes previously associated with metastasis. In vitro studies have demonstrated that Areg 26 , Tead1 81 , Coro1C 69 , Lama5 22 , Tgm2 45 and Fgf 7 79 are involved in cell migration and invasion features of tumor cells. The reduced expression of these genes involved in invasion phenotypes may provide additional mechanistic information to explain our previous finding that E2F1 -/tumors had possible invasion/intravasation problems indicated by a reduction in circulating tumor cells 30 .
The data presented here also demonstrated a role for Fgf13 in metastasis. Fgf13 is a nonsecretory protein of the FGF family 75 and we show that loss of Fgf13 in tumor cells blocked colonization of the lungs in a tail vein injection setting. In order to investigate the mechanism for this block of metastatic capacity, we identified that genes that co-vary with Fgf13 using WGCNA. Amongst these genes, we noted several genes associated with cell motility were in an interaction network with FGF13. This led us to predict that FGF13 may function in cell migration. We confirmed this prediction using a scratch assay where both Fgf13 knockout clones demonstrated impaired cell migration. Interestingly, the role of Fgf13 in neuron development also highlights its role in cell migration while detailing a mechanism of Fgf13 induced microtubule stabilization 75 . Within the Fgf13 covariate network, we also observe many genes consistent with microtubule stabilization and neuron development ( Table 1 ). This agreement between the two studies might suggest conserved mechanisms for cell migration in tumor cells and in neurons. Further, drawing from our study and that of Wu et al. 75 predicts that the possible function of Fgf13 in metastasis may be attributed to a function in cell migration via microtubule stabilization.
As a whole, this study shows that the metastatic defects associated with E2F1 loss could be due to an inability to properly initiate a gene expression response to hypoxia. Importantly, many of the genes downregulated in E2F1 -/tumors associated with hypoxia response have been shown as regulators breast cancer metastasis. We identified that the E2F1 target gene Fgf13 controls pulmonary metastasis, potentially through a cell migration mechanism; possibly providing a means for E2F1 to regulate cell migration. Collectively, this study furthers our initial characterization of E2F1's regulation of metastasis by identifying the metastasis associated gene expression response to E2F1 loss.
METHODS
RNA AND MICROARRAY
Preparation of RNA samples from flash frozen tumors was done using the Qiagen RNeasy kit after roto-stator homogenization. RNA from 17 Myc induced tumors was submitted to the Michigan State University Genomics Core facility for gene expression analysis using Mouse 430A 2.0 Affymetrix arrays.
GENE EXPRESSION ANALYSIS
Raw intensity .CEL files were processed and RMA normalized using Affymetrix
Expression Console. Gene expression data is deposited on the Gene Expression Omnibus under the accession number GSE104397. Unsupervised class discovery was done using Consensus
Cluster Plus 73 . For class discovery, we mapped Affymetrix probes to their gene symbol using the platform table deposited on the Gene Expression Omnibus (GPL8321). Given the presence of multiple probes for single genes, we collapsed duplicate genes to their mean expression in each sample. This approach reduced our dataset of 22690 probes down to 12847 gene symbols. Next, we median centered the gene expression values across the samples in the dataset. Finally, we filtered genes using a requirement of a standard deviation greater than 0.5. This resulted in 1,303 genes used for class discovery and consensus clustering. We used 1,000 iterations and 90% item (sample) resampling to evaluate 2-10 potential clusters (groups/classes). Consensus cumulative distribution function (CDF) plots are also generated using Consensus Cluster Plus 73 . Silhouette width 58 was used to assess validity of each cluster using the R package 'Cluster' 52 . Pathway activation was predicted according to previous studies 6, 21, 28 . Single sample gene set enrichment analysis was done for Hallmark 41 gene sets using the ssGSEAProjection module on Broad Institute's Gene Pattern 57 . Significance analysis of microarrays 67 was used to compare E2F WT/WT and E2F1 -/tumors in a fold change analysis. Direct E2F1 target genes were identified using ChIP-base 77 and data from a previous ChIP-seq experiment 5 . Kaplan-Meier plots were generated using using KMPLOT.com to query human breast cancer expression and clinical data 64 . Significant overlaps with previously established gene sets were detected using the molecular signatures database 41 . Interaction networks were assembled using www.string-db.org 19 . Weighted correlation network analysis was implemented according to published protocols 38 and using a gene significance score threshold of 0.6 to select genes for further analysis.
CELL CULTURE
MMTV-PyMT 419 cells were a gift from Dr. Stuart Sell and Dr. Ian Guessand have been previously characterized 44 . All tumor cells were cultured in Dulbecco's Modified Eagle's Medium, 3.7 g/L of NaHCO3, 3.5 g/L d-glucose, 5ug/mL insulin, 1ug/mL hydrocortisone, 5ng/mL Egf, 35ug/mL BPE, 50ug/mL gentamicin, 1X Antibiotic/Antimycotic, and 10% fetal bovine serum. Media was set to a pH of 7.4.
CRISPR
Sequence for Fgf13 was obtained from the UCSC genome browser 36 . Guide sequences were predicted by submitting exon (using only those that were common across all Fgf13 isoforms) sequence using the CRISPR design tool at: http://crispr.mit.edu/. Oligos for guide sequence assembly were designed by adding a 'G' followed by 'CACC' at the 5' end of the guide sequence. For the complementary DNA to the guide, add 'CAAA' to the 5' end.
Oligonucleotide sequences are as follows: degrees Celsius for 4 minutes, and then cooled to room temperature. The annealed oligonucleotides were inserted into the PX458 vector from Addgene (#48138). Confirmation of the cloned guide sequence was done using Sanger sequencing.
PyMT 419 cells were transfected according to a previously described protocol 40 . To select clones, GFP positive cells were sorted into 96 well plates using fluorescence activated cell sorting. Knockout clones were screened for by PCR amplifying a ~300 bp amplicon with the PAM sequence centrally located within the PCR product. PCR products were resolved on a 3% agarose gel, extracted with the QIAquick Gel Extraction Kit, and were submitted for sanger sequencing.
PCR Amplification Primers: Fgf13 5': 5'-TGTTCTAACTTCCAGAAAGGCATA-3' Fgf13 3': 5'-CAGTGGTTTGGGCAGAAAAT-3'
For sequencing, a nested primer with the following sequence was used. for beta-actin we used a monoclonal antibody (Cell Signaling #4970). The Fgf13 ORF was purchased from GenScript in the pcDNA3.1 vector and were subsequently digested with EcoRI and XhoI cloned into the EcoRI and XhoI sites of pLXSN. Retrovirus was packaged in HEK-293GPG as previously described (90). Briefly, a confluent 10-cm plate of HEK-293GPG cells was transfected with 5 µg of pLXSN-mADM or pLXSN-mFGF13 and virus containing media was subsequently harvested. Subconfluent 10 cm plates (~20%confluence) of 419 cells were infected with 1 mL of non-concentrated viral supernatant and infected cells were selected with 300 µg/mL G418.
IN VITRO ASSAYS
To measure cell migration, wound healing assays were performed in the presence of 2ug/mL Mitomycin C using standard methods 60 . Photomicrographs were taken at 0 hour and 18 hours.
IN VIVO ASSAYS
Animal protocols used for this study were approved by Michigan State University IACUC Committee and conducted according to national and institutional guidelines. All mice were in the FVB background. For tail vein injection, MMTV-Cre control mice were used to avoid immune response to the middle T antigen 17, 43, 56 . For control cells and each knockout clone, 50,000 cells were injected into the bloodstream via the tail vein. After 21 days, mice were euthanized. Lungs were resected for H&E staining to detect metastases. To calculate significance, unpaired T-tests were done in graphpad prism.
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